AI assistant
Wave Life Sciences Ltd. — Director's Dealing 2023
Aug 24, 2023
31900_dirs_2023-08-23_064a2726-9d14-4865-ac90-ceb2141df309.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Wave Life Sciences Ltd. (WVE)
CIK: 0001631574
Period of Report: 2023-08-23
Reporting Person: Moran Kyle (Chief Financial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-08-23 | Ordinary Shares | S | 37062 | $4.752 | Disposed | 46120 | Direct |
Footnotes
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 10, 2023.
F2: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $4.75 to $4.76 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
F3: Includes 3,431 ordinary shares acquired on July 14, 2023, under the issuer's 2019 Employee Share Purchase Plan.